Research programme: ROR gammaT antagonists - Immunic

Drug Profile

Research programme: ROR gammaT antagonists - Immunic

Alternative Names: IMU-366

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Immunological disorders; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 28 Sep 2016 Immunic Therapeutics acquires IMU-366 programme from 4SC
  • 28 Sep 2016 Early research in Autoimmune disorders in Germany before September 2016 (PO)
  • 28 Sep 2016 Early research in Immunological disorders in Germany before September 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top